Details for New Drug Application (NDA): 201110
✉ Email this page to a colleague
NDA 201110 describes MILPROSA, which is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are three patents protecting this drug. Additional details are available on the MILPROSA profile page.
The generic ingredient in MILPROSA is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the progesterone profile page.
The generic ingredient in MILPROSA is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the progesterone profile page.
Summary for 201110
| Tradename: | MILPROSA |
| Applicant: | Ferring Pharms Inc |
| Ingredient: | progesterone |
| Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 201110
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYSTEM;VAGINAL | Strength | 1.78GM | ||||
| Approval Date: | Apr 29, 2020 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 3, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 3, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 21, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN | ||||||||
Complete Access Available with Subscription
